Choline chloride

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Friday, April 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.

Insights on the Choline Chloride Global Market to 2027 - Featuring Balaji Amines, Balchem and BASF Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 14, 2021
Chemicals, Plastics, Manufacturing, Poultry feed, Growth, Choline chloride, COVID-19, CAGR, Pet

The "Choline Chloride - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Choline Chloride - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Choline Chloride estimated at 543.6 Thousand Tons in the year 2020, is projected to reach a revised size of 703.8 Thousand Tons by 2027, growing at a CAGR of 3.8% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at 146.6 Thousand Tons, While China is Forecast to Grow at 6.9% CAGR
    The Choline Chloride market in the U.S. is estimated at 146.6 Thousand Tons in the year 2020.
  • In the global Other Applications segment, USA, Canada, Japan, China and Europe will drive the 2.1% CAGR estimated for this segment.

Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Monday, September 13, 2021
Choline, Pathology, Food, Therapy, Incidence, ALP, Short bowel syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, University, University of Illinois Urbana-Champaign, Regius Professor of Clinical Surgery, Liver disease, Parenteral nutrition, Patient, Â, Company, Liver, Cholestasis, Private Securities Litigation Reform Act, Phospholipid, Odds, Nasdaq, U.S. Securities and Exchange Commission, Medical director, Steatosis, PN, Death, COVID-19, Microcystic lymphatic malformation, Observational study, Partnership, GLOBE, Population, Risk, Choline chloride, Cancer, Prevalence, ULN, Pharmaceutical industry, Medical imaging, Risk management, Health insurance

NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the completion of a retrospective prevalence study designed to enhance understanding of the incidence of intestinal failure associated liver disease (IFALD) in patients dependent on parenteral nutrition (PN). The study found that approximately 30% of patients who are dependent on PN have cholestasis, a hallmark pathology of IFALD, despite the use of current medical management in these patients. The Company is currently developing intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement therapy, for the treatment of patients receiving PN who have IFALD.

Key Points: 
  • The study found that approximately 30% of patients who are dependent on PN have cholestasis, a hallmark pathology of IFALD, despite the use of current medical management in these patients.
  • Results from the previously completed Phase 2 study of IV Choline Chloride support the clinical potential of choline substrate replacement therapy to treat IFALD.
  • The Company expects to use the results from the completed retrospective study and ongoing prospective study to inform next steps for its IV Choline Chloride development program.
  • The retrospective, observational study was conducted in partnership with a large home health organization and examined data from 468 patients dependent on PN for six months or more.

Global Choline Chloride Market Analysis & Forecast Report, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Chemicals, Plastics, Health, Manufacturing, Fitness & Nutrition, Agriculture, Natural Resources, Nature, Choline, Industry, Competition, Value, Population, Company, Kemin Industries, Metabolism, Aquaculture, Choline chloride, BASF, Animal, Growth, Form, Chondrodystrophy, Water, Powder, Nutreco, COVID-19, Awareness, Liver, Eastman Chemical Company, Hepatomegaly, Animal feed, Poultry

The "Global Choline Chloride Market (Value, Volume) - Analysis By Form, End-User, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Choline Chloride Market (Value, Volume) - Analysis By Form, End-User, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The report presents the analysis of Choline Chloride market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • Among the Forms in the Choline Chloride market (Powder and Liquid), Liquid segment leads the market.
  • High demand for choline chloride, along with growing population in this region, is creating a strong need for choline chloride market.

The global choline chloride market accounted for US$ 662.5 Mn in 2018 and is expected to grow at a CAGR of 5.0% during the forecast period 2019 - 2027, to account to US$ 1,019.5 Mn by 2027

Retrieved on: 
Wednesday, November 27, 2019
Quaternary ammonium compounds, Primary alcohols, Cholinergics, Chemistry, Choline chloride, Choline, Health, Quaternary ammonium cation, Chemical substances

The global choline chloride market accounted for US$ 662.5 Mn in 2018 and is expected to grow at a CAGR of 5.0% during the forecast period 2019 - 2027, to account to US$ 1,019.5 Mn by 2027.

Key Points: 
  • The global choline chloride market accounted for US$ 662.5 Mn in 2018 and is expected to grow at a CAGR of 5.0% during the forecast period 2019 - 2027, to account to US$ 1,019.5 Mn by 2027.
  • Choline chloride is defined as an organic compound containing both quaternary ammonium salt and alcohol and is bi-functional.
  • Choline chloride has also found a profound place in the feed and oil and gas industry and has been estimated to create a significant opportunity for the choline chloride market all over the globe.
  • The increasing awareness and implementation of choline chloride coupled, with the functional properties of choline, have also favored the choline chloride market growth all over the globe.